Title:Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Volume: 22
Issue: 13
Author(s): Phool Chandra*, Neetu Sachan and Dilipkumar Pal
Affiliation:
- Department of Physiology & Pharmacology, School of Pharmaceutical Sciences, IFTM University, Lodhipur Rajput, Delhi Road (NH-24), Moradabad-244 102 (U.P.),India
Keywords:
Glycogen synthase kinase-3, breast cancer, ovarian cancer, tumor, cell cycle, proliferation.
Abstract: A serine/threonine-protein kinase, recognized as Glycogen Synthase Kinase-3 (GSK-3),
is documented as a regulator of assorted cellular roles. GSK-3 activates by phosphorylation and
thereby controls the action of many physiological, messenger, and membrane-bound structures.
GSK-3α and GSK-3β are two vastly homologous forms of GSK-3 in mammals. Recent information
has recommended that GSK-3β is a constructive controller of cancer cell proliferation and a
promising key target against cancer cells. GSK-3 is overexpressed in various tumor types, including
ovarian tumors. In human breast carcinoma, it has been revealed that the overexpression of
GSK-3β was linked with breast cancer patients. The inhibition of GSK-3 or inhibitors of GSK-3 is
a promising therapeutic tactic to overcome breast and ovarian cancer. This article features an important
aspect of inhibitors of Glycogen Synthase Kinase-3 as a new lead for treating breast and
ovarian Cancer.
